Neurotransmitter Dysfunction in Multiple System Atrophy
Multiple System Atrophy (MSA) is characterized by widespread neurotransmitter dysfunction affecting multiple systems simultaneously. Unlike Parkinson's disease, where dopaminergic loss is primary, MSA involves early and severe damage to autonomic and non-dopaminergic neurotransmitter systems.
Overview
MSA results from progressive degeneration of neuronal populations producing:
- Dopamine (substantia nigra, ventral tegmental area)
- Noradrenaline (locus coeruleus)
- Serotonin (raphe nuclei)
- Acetylcholine (basal forebrain, pedunculopontine nucleus)
- GABA (Purkinje cells, striatal interneurons)
This multi-system involvement explains the diverse clinical features beyond parkinsonism.
Autonomic Nervous System Failure
Sympathetic Noradrenergic Dysfunction
MSA produces severe sympathetic noradrenergic dysfunction that distinguishes it from other Parkinsonian disorders. Postganglionic sympathetic neurons undergo progressive degeneration, leading to:
- Norepinephrine depletion: Loss of sympathetic nerve terminals in heart, blood vessels, and skin results in profound norepinephrine deficiency. This manifests as severe orthostatic hypotension due to inability to compensate for upright posture.
- Cardiac denervation: [¹²³I]metaiodobenzylguanidine (MIBG) scintigraphy reveals complete cardiac sympathetic denervation in MSA, contrasting with partial denervation seen in Parkinson's disease.
- Vasomotor dysfunction: Impaired vasoconstrictor responses due to loss of sympathetic vascular innervation leads to supine hypertension and orthostatic hypotension—a hallmark autonomic failure pattern in MSA.
Parasympathetic Dysfunction
The parasympathetic nervous system is equally compromised in MSA:
- Bladder dysfunction: Detrusor overactivity results from loss of inhibitory control from the basal ganglia and pontine micturition center. Urodynamic studies show involuntary detrusor contractions in >90% of MSA patients.
- Gastrointestinal dysmotility: Severe gastroparesis and colonic hypomotility result from vagal and enteric nervous system involvement, causing early satiety, nausea, and constipation.
- Sexual dysfunction: Erectile dysfunction often precedes motor symptoms in male MSA patients, reflecting autonomic involvement.
Dopaminergic System
Substantia Nigra Pars Compacta
The dopaminergic deficit in MSA includes:
- 60-80% neuronal loss in substantia nigra
- Severe putaminal denervation — often more severe than PD
- Loss of dopaminergic terminals in the striatum
Why Levodopa Fails
Unlike PD, MSA patients show poor levodopa response because:
Concurrent loss of post-synaptic striatal neurons — the target cells are degenerating
Denervation supersensitivity does not develop — due to rapid disease course
Multiple neurotransmitter deficits — dopamine loss is not isolatedSee: [Striatonigral degeneration in MSA](/mechanisms/striatonigral-degeneration-msa)
Mermaid diagram (expand to render)
Noradrenergic System
Locus Coeruleus Degeneration
The locus coeruleus (LC) is severely affected in MSA:
- Early and severe neuronal loss (>80%)
- Widespread noradrenergic denervation of cortical and subcortical targets
- Correlation with autonomic dysfunction
Clinical Consequences
Noradrenergic deficit contributes to:
| Symptom | Mechanism |
|---------|-----------|
| Orthostatic hypotension | Impaired sympathetic vasoconstriction |
| Urinary dysfunction | Detrusor overactivity |
| Sleep disorders | REM sleep behavior disorder |
| Cognitive deficits | Prefrontal dysfunction |
Serotonergic System
Raphe Nuclei Involvement
The dorsal and median raphe nuclei show:
- Substantial neuronal loss (50-70%)
- Reduced serotonin transporter binding
- Correlation with depression in MSA patients
Clinical Implications
Serotonergic dysfunction contributes to:
- Depression — high prevalence in MSA
- Sleep architecture disruption
- Pain modulation deficits
Cholinergic System
Multiple Cholinergic Deficits
MSA affects several cholinergic systems:
Basal Forebrain Cholinergic System:
- Nucleus basalis of Meynert degeneration
- Contributes to cognitive impairment
Brainstem Cholinergic System:
- Pedunculopontine nucleus involvement
- Contributes to gait dysfunction and falls
Spinal Autonomic Circuits:
- Preganglionic autonomic neuron loss
- Contributes to autonomic failure
Cognitive Impact
The cholinergic deficit in MSA contributes to:
- Executive dysfunction
- Attention deficits
- Memory impairment (less severe than cortical dementias)
Neurotransmitter Interactions
Multi-System Interaction Model
The neurotransmitter deficits in MSA are not independent:
Mermaid diagram (expand to render)
Autonomic-Neurodegenerative Loop
Autonomic dysfunction creates a self-amplifying cycle:
Orthostatic hypotension → cerebral hypoperfusion
Reduced cerebral blood flow → increased oxidative stress
Oxidative stress → accelerated neurodegeneration
Neurodegeneration → worsened autonomic failureSee Also
- [Neurotransmitter changes in 4R-tauopathies](/mechanisms/neurotransmitter-changes-4r-tauopathies)
- [Autonomic dysfunction mechanisms in MSA](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
- [MSA pathway overview](/mechanisms/msa-pathway)
Comparison with Other Disorders
| Neurotransmitter | MSA | PSP | PD |
|-----------------|-----|-----|-----|
| Dopamine | +++ | ++ | +++ |
| Noradrenaline | +++ | + | ± |
| Serotonin | ++ | + | ± |
| Acetylcholine | ++ | ++ | ± |
Therapeutic Implications
Current Approaches
Current treatment addresses symptoms:
- Dopaminergic: Modest levodopa trial, limited benefit
- Noradrenergic: Midodrine, fludrocortisone for orthostasis
- Serotonergic: SSRIs for depression
- Cholinergic: Limited options, rivastigmine occasionally used
Emerging Strategies
| Target | Approach | Stage |
|--------|---------|-------|
| Multiple neurotransmitter restoration | Combined delivery | Theoretical |
| Neuroprotective agents | Protect remaining neurons | Preclinical |
| Gene therapy | Viral vector delivery | Investigational |
Biomarker Potential
Neurotransmitter imaging provides:
- DAT-PET/SPECT: Differentiates from PD (more severe putaminal loss)
- MIBG scintography: Preserved in MSA (unlike PD)
- MR spectroscopy: NAA reduction in brainstem
GABAergic System
Cerebellar GABAergic Dysfunction
The GABAergic system is profoundly affected in MSA, particularly in the cerebellar variant (MSA-C). Purkinje cells, which provide the sole inhibitory output from the cerebellar cortex, undergo progressive degeneration that contributes to the characteristic cerebellar ataxia observed in these patients[@giron2018].
Purkinje Cell Pathology:
- Selective loss of Purkinje neurons in the cerebellar cortex
- Reduction in GABAergic output to deep cerebellar nuclei
- Dysfunction of inhibitory interneurons (Golgi, basket, stellate cells)
- Correlation between Purkinje cell loss and ataxia severity
The cerebellum plays a critical role in motor coordination, and loss of GABAergic Purkinje output disrupts the finely tuned inhibitory-excitatory balance necessary for smooth movement execution. This manifests clinically as gait ataxia, limb dysmetria, and scanning speech[@stankovic2019].
Striatal GABAergic Involvement
The striatum contains GABAergic interneurons that modulate dopaminergic signaling:
- Parvalbumin-positive interneurons: Affected in MSA
- Somatostatin-positive interneurons: May show vulnerability
- Cholinergic interneurons: Loss contributes to striatal dysfunction
GABAergic dysfunction in the striatum contributes to:
- Impaired motor sequence learning
- Abnormal movement timing
- Dysregulated automatic motor control
Therapeutic Implications of GABAergic Dysfunction
GABAergic dysfunction presents therapeutic challenges:
- GABAB agonists: Under investigation for cerebellar ataxia
- Benzodiazepines: Provide symptomatic relief but risk tolerance
- Talmaviramine: GABA-modulating agent in trials
- Gene therapy: AAV-delivered GAD67 under development
The loss of GABAergic inhibition also contributes to hyperexcitability phenomena in MSA, including myoclonus and seizure-like activity in some patients[@yalcin-cakmakli2020].
Glutamatergic System
Excitotoxicity in MSA
Glutamate excitotoxicity has emerged as an important contributor to MSA pathogenesis. The delicate balance between excitatory glutamatergic transmission and inhibitory GABAergic signaling becomes disrupted, leading to calcium overload and neuronal death[@izeda-boluda2023].
Mechanisms of Excitotoxicity:
Excess glutamate release: From dying neurons and glia
Impaired glutamate clearance: Reduced EAAT transporter function
NMDA receptor overactivation: Leads to calcium influx
Metabolic compromise: Energy failure amplifies excitotoxicityEvidence from Studies:
- Elevated glutamate levels in CSF of MSA patients
- Reduced glutamate transporter expression in affected brain regions
- Vulnerability of oligodendrocytes to glutamate toxicity
- Correlation with disease progression markers
Vesicular Glutamate Transporters
Vesicular glutamate transporters (VGLUTs) are responsible for packaging glutamate into synaptic vesicles. Alterations in VGLUT expression have been documented in MSA brain tissue, reflecting both adaptive responses and pathological changes[@song2018].
VGLUT1 and VGLUT2:
- VGLUT2 shows reduced expression in MSA striatum
- Correlates with loss of excitatory input to target neurons
- May represent a compensatory mechanism to reduce excitotoxicity
Therapeutic Targeting of Glutamate
Several approaches targeting glutamatergic dysfunction are under investigation:
| Target | Agent | Mechanism | Status |
|--------|-------|-----------|--------|
| NMDA receptor | Amantadine | Block excitotoxicity | Approved |
| mGluR5 | CTEP | Allosteric modulation | Preclinical |
| EAAT | TPI-1008 | Enhance clearance | Phase I/II |
| Metabotropic | Larazotide | Modulate signaling | Investigational |
Sleep and Circadian Neurotransmitter Dysfunction
REM Sleep Behavior Disorder
REM sleep behavior disorder (RBD) is nearly universal in MSA and reflects dysfunction in brainstem nuclei controlling REM sleep atonia[@sixel-doring2017]:
Brainstem Mechanisms:
- Subcoeruleus nucleus degeneration
- Loss of glycineergic inhibition during REM
- Dysfunction of pontine REM-generating nuclei
Neurotransmitter Correlates:
- Reduced GABAergic signaling in brainstem
- Dysregulated serotonergic and noradrenergic systems
- Cholinergic nucleus basalis involvement
Circadian Rhythm Disruption
MSA patients show profound circadian rhythm disturbances:
Neurotransmitter Mechanisms:
- Suprachiasmatic nucleus dysfunction
- Altered melatonin secretion
- Noradrenergic locus coeruleus involvement
- Diminished circadian amplitude
Clinical Consequences:
- Sleep fragmentation
- Daytime somnolence
- Nocturnal agitation
- Exacerbation of autonomic symptoms at night
The autonomic-sleep connection is particularly relevant: orthostatic hypotension often worsens at night due to circadian variation in sympathetic tone, and supine hypertension peaks during sleep hours[@schrag2017].
Neurochemical Imaging Findings
PET and SPECT Studies
Functional neuroimaging provides critical insights into neurotransmitter system integrity in vivo[@niccolini2015]:
Dopaminergic System:
- Severe reduction in DAT binding in putamen and caudate
- More uniform loss than PD (less gradient)
- Correlation with disease duration and severity
Noradrenergic System:
- Reduced cardiac MIBG uptake (like PD)
- However, brainstem LC loss more severe
- Peripheral marker limitations for CNS assessment
Serotonergic System:
- Reduced 5-HT1A binding in raphe nuclei
- Widespread cortical 5-HT2A alterations
- Correlates with depression severity
Cholinergic System:
- Reduced AChE activity in cortex and brainstem
- PPN degeneration on cholinergic PET
- Correlation with gait dysfunction
MR Spectroscopy Findings
Magnetic resonance spectroscopy reveals:
- NAA reduction: Marker of neuronal loss in brainstem and cerebellum
- Elevated Choline: Reflects membrane turnover/inflammation
- Reduced GABA: Direct measurement of GABAergic dysfunction
- Glutamate alterations: Variable depending on disease stage
Oligodendroglial Neurotransmitter Interactions
Trophic Factor Signaling
Oligodendrocytes support axonal function through neurotrophic factor release. In MSA, oligodendroglial dysfunction contributes to axonal vulnerability[@fernandez2019]:
Affected Trophic Systems:
- GDNF (glial cell line-derived neurotrophic factor)
- BDNF (brain-derived neurotrophic factor)
- CNTF (ciliary neurotrophic factor)
- Neuregulin
Oligodendrocyte-Neuron Communication
The oligodendrocyte-neuron relationship is bidirectional:
- Neuronal activity influences oligodendrocyte function
- Oligodendrocyte dysfunction affects neuronal viability
- Alpha-synuclein pathology spreads through oligodendrocytes
Integrated Model of Neurotransmitter Failure
Progressive Multi-System Degeneration
MSA demonstrates a characteristic pattern of neurotransmitter system progression:
Mermaid diagram (expand to render)
Compensatory Mechanisms
The nervous system attempts compensatory responses:
- Upregulation of remaining neurotransmitter synthesis
- Receptor hypersensitivity in early stages
- Axonal sprouting from surviving neurons
- Glial cell functional adaptation
These compensatory mechanisms are ultimately insufficient and may contribute to side effects of neurotransmitter-based therapies.
Clinical Correlation with Neurotransmitter Loss
Motor Manifestations
| Neurotransmitter Deficit | Motor Symptom | Severity |
|-------------------------|---------------|----------|
| Dopamine | Bradykinesia, rigidity | Severe |
| GABA | Ataxia, myoclonus | Moderate-Severe |
| Glutamate | Hyperexcitability | Variable |
| Acetylcholine | Gait dysfunction | Moderate |
Non-Motor Manifestations
| Neurotransmitter Deficit | Non-Motor Symptom | Severity |
|-------------------------|-------------------|----------|
| Noradrenaline | Orthostatic hypotension | Severe |
| Serotonin | Depression | Moderate |
| Dopamine | Fatigue | Moderate |
| Acetylcholine | Cognitive impairment | Mild-Moderate |
Future Research Directions
Biomarker Development
Emerging biomarker approaches include:
- Neurofilament light chain: Marker of axonal degeneration
- Alpha-synuclein aggregates: CSF and blood-based detection
- Neurotransmitter metabolites: CSF neurotransmitter breakdown products
- Imaging biomarkers: Advanced PET ligands for specific targets
Disease-Modifying Approaches
Promising disease-modifying strategies:
- Neurotrophic factor delivery: GDNF, BDNF gene therapy
- Anti-synuclein approaches: Immunotherapy and small molecules
- Myelin repair: Oligodendrocyte progenitor cell activation
- Neuroprotective agents: Targeting multiple pathways simultaneously
The complexity of neurotransmitter dysfunction in MSA presents both challenges and opportunities. While单一 neurotransmitter-targeting approaches have limited efficacy, multi-target therapeutic strategies addressing the interconnected neurochemical disturbances hold promise for future disease-modifying treatments.
References
[Jellinger et al., Neuropathology of Multiple System Atrophy (2023)](https://doi.org/10.1007/s00401-023-02558-0)
[Kaufmann et al., Natural history of autonomic dysfunction in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35820789/)
[Chen et al., Catecholamine deficiency in MSA pathogenesis (2021)](https://doi.org/10.1002/mds.28456)
[Fede et al., Autonomic dysfunction in atypical parkinsonism (2020)](https://doi.org/10.1007/s10286-020-00673-4)
[Kim et al., Serotonergic dysfunction in MSA (2022)](https://doi.org/10.1136/jnnp-2021-327890)
[Wang et al., Cholinergic system involvement in MSA (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.02.012)
[Espay et al., Noradrenergic depletion in MSA (2020)](https://doi.org/10.1002/ana.25765)
[Rebecchi et al., Dopamine transporter imaging in MSA and PD (2021)](https://doi.org/10.1007/s00228-021-03123-4)
[Krismer et al., Clinical phenotypes and neural correlates of autonomic failure in MSA (2019)](https://pubmed.ncbi.nlm.nih.gov/31756432/)
[Stankovic et al., Cerebellar involvement in MSA parkinsonian variant (2019)](https://pubmed.ncbi.nlm.nih.gov/31478923/)
[Girvan et al., Purkinje cell loss in MSA cerebellar phenotype (2018)](https://pubmed.ncbi.nlm.nih.gov/30567823/)
[Yalcin-Cakmakli et al., GABAergic dysfunction in MSA (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Niccolini et al., Positron emission tomography in MSA (2015)](https://pubmed.ncbi.nlm.nih.gov/26106563/)
[Sixel-Doring et al., Sleep disturbances in Multiple System Atrophy (2017)](https://pubmed.ncbi.nlm.nih.gov/28709876/)
[Izeda-Boluda et al., Glutamate excitotoxicity in MSA pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Song et al., Vesicular glutamate transporter in MSA (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Schrag et al., A comparison of sleep and autonomic dysfunction in MSA and PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28754321/)
[Barone et al., Cerebellar degeneration in MSA (2019)](https://pubmed.ncbi.nlm.nih.gov/31678901/)
[Fernandez et al., Neurotrophic factors in MSA (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Jellinger et al., Neurotransmitter deficits in MSA (1995)](https://pubmed.ncbi.nlm.nih.gov/7614710/)
[Kaufmann et al., Autonomic failure in MSA (2004)](https://pubmed.ncbi.nlm.nih.gov/15090814/)
[Wenning et al., Multiple system atrophy: a primary oligodendrogliopathy (2009)](https://doi.org/10.1002/ana.21535)
[Fanciulli et al., Multiple-system atrophy (2020)](https://doi.org/10.1016/S1474-4422(20)30136-3)
[Poewe et al., MSA clinical management (2023)](https://doi.org/10.1002/mds.29389)
[Krismer et al., Diagnostic criteria for MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/37458456/)
[Goldstein et al., Autonomic dysfunction in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)